- What’s the deal with insurer mental health parity violations?
- Drugmaker recalls Xanax over quality issue
- NYU Langone Health opens 12K-square-foot ambulatory location
- 10 anesthesia leadership appointments from Q1
- What could improve physician market competition
- Remarks at the Options Market Structure Roundtable
- Wider care gaps predicted as mental health parity rule faces rollback
- Beyond March Madness: Athletics boost academic health system marketing
- Sheppard Pratt gets $16.5M for behavioral health expansion
- How ESOPs can help retiring physicians cash out
- Specialty1 Partners’ growth in 2026: 5 updates
- North Carolina system invests $200M in cancer care
- UnityPoint Health to transition dental services to FQHC
- The ownership opportunity ASCs are leaving behind
- New York hospital taps ambulatory operations leader
- 10 trends in behavioral health usage: Report
- How hospitals are winning — and losing — the ASC moment
- 4 DSOs adding new technology
- Hawaii system names interim CEO
- Aspen Dental opens Michigan office
- Turning Fragmented Clinical Data into Actionable Insight
- Ascension taps president for 2 Texas hospitals
- Colorado hospital saves money by dual training clinicians as interpreters
- Walmart expands GLP-1 care, pharmacy integration
- Mississippi hospital files for bankruptcy
- Studies reaffirm fluoride safety, benefits: 10 things to know
- Philips earns FDA clearance for spectral CT with cardiac imaging
- Pennsylvania hospital shifts to outpatient-focused model
- New Oklahoma law closes dental insurer price fixing loophole
- Cattywampus: Statement on the CAT Concept Release
- Nicklaus Children’s performs Florida’s 1st partial heart transplant
- One Lot of Xanax Recalled Nationwide Over Quality Issue, FDA Says
- Butterflies and Condors: Remarks at the Options Market Roundtable
- Viatris, Teva kick off separate recalls over dissolution, raw material issues
- Why tech, workforce are key to Prisma outpatient pharmacy growth
- Rising ACA Costs Leave Many Unable To Pay for Coverage
- Cough Drops From Several Brands Being Recalled, FDA Says
- CDC May Get New Leader as Officials Consider Erica Schwartz
- Mental health ED visits at Children’s Hospital Colorado jump 20% in April
- Statement at the Roundtable on Options
- Opening Remarks at the Options Market Structure Roundtable
- New Alzheimer's Drugs Provide No Meaningful Benefit, Major Evidence Review Concludes
- This Simple Step Could Improve The Benefits From Your Regular Workouts
- E-Bikes And E-Scooters A Growing Menace On City Streets, Study Says
- 'Absent or trivial' effects: Anti-amyloid Alzheimer's drugs called into question once again
- Why Walking Remains Unsteady After Partial Spinal Cord Injury
- Study Says Stress, Weight And Hormones Alter Timing of Puberty in Girls
- RFK Jr. kicks off string of congressional hearings to talk White House budget plan
- Air Pollution and Weather Tied to Migraines
- Roche to launch another Elevidys study after EU rejection of Duchenne gene therapy
- Lilly answers FDA's call for more Foundayo safety info, plotting diabetes filing in parallel
- New Federal Medicaid Rules Require One Month of Work. Some States Demand More.
- As US Birth Rate Falls, Feds’ Response May Make Pregnancy More Dangerous
- Omnicom brews Olixir from FCB Health, rebranding storied agency after Interpublic takeover
- DiMe-led initiative brings together pharma, virtual providers, digital pharmacies to develop blueprint for DTC pharma models
- Kentucky approves changes to Dental Practice Act
- Former Utah dentist accused of practicing dentistry without a license
- 7 dental companies gaining new funding
- Heartland Dental adds Michigan practice
- UPDATED: Heeding RFK Jr.'s call, FDA reclassifies 12 unapproved peptides ahead of advisory committee meeting
- Carrot launches proprietary AI platform for personalized fertility, family care
- UC Health workers plan open-ended, system-wide strike for May 14
- Baylor Scott & White Health Plan to depart individual market, Medicaid this year
- In industry's latest OTC pivot, Daiichi Sankyo lines up $1.5B consumer health unit sale to beverage giant Suntory
- Wildlife Trade Tied To Higher Risk of Diseases Spreading to Humans
- EPA Delays Decisions on 'Forever Chemicals'
- Yes, This is the Worst Pollen Season Ever — Until Next Year
- ‘Mini specialists’: 5 models reshaping behavioral health in primary care
- GoodRx launches 7.2-mg Wegovy dose for self-pay patients at $399 per month
- Providers back bipartisan bill eliminating Medicare chronic care management cost sharing
- Progyny unveils new fertility benefit option for small, mid-size employers
- New Weight Loss Pill, Foundayo, Gets Approval But FDA Seeks More Safety Data
- Seqster launches new data tool to turn clinical sites into 'research-ready data collection points'
- Gilead widens global Yeztugo access agreement, but MSF says supply is 'not nearly enough'
- Novartis CEO Vas Narasimhan joins Anthropic’s board as biopharma’s ties to AI deepen
- Behavioral health utilization is up with anxiety disorders leading demand, report finds
- Does Your Child Have A Concussion? These Are The Signs, Review Says
- AI Reveals Negative Labels in Medical Records for Sickle Cell Patients
- 'Food-as-Medicine' Improves Life for Heart Failure Patients
- Silent Heart Rhythm Problem Might Triple Risk Of Heart Failure In Seniors
- Blood Test Predicts Alzheimer's Years Before Symptoms, Brain Changes
- An Infectious Combo Triples Risk Of MS, Study Says
- Astellas manufacturing chief views reliable supply, bridging research as his production 'north star'
- Physician compensation up 3% in 2025, but not all specialties saw raises: Medscape
- Pfizer recruits former Angel Lucy Liu for latest mission against cancer
- Teva launches new online schizophrenia community project
- One man’s journey from gambling addiction to recovery and advocacy
- Medi-Cal Immigrant Enrollment Is Dropping. Researchers Point to Trump’s Policies.
- Rural Nebraska Dialysis Unit Closes Despite the State’s $219M in Rural Health Funding
- Ionis exec shares method to the Madness after 2026 Drug Name Tournament win
- Chicago hospital expands outpatient, walk-in mental health services
- Abridge expands clinical decision support solution with UpToDate partnership, new NEJM, JAMA content tie-ups
- Travere maps course for Filspari's $3B US opportunity after landmark rare disease nod
- Hospitals with more disadvantaged patients fall short on price transparency, study finds
- FDA tells Eli Lilly to round up more safety info on key obesity launch Foundayo
- Meat Consumption Rises as Protein Trend Grows, Experts Warn
- Bill would force payers to apply DTC drug purchases to patient deductibles
- Bill would force payers to apply DTC drug purchases to patient deductibles
- 43 states have mental health insurance disparities: 4 trends
- Nuts.com Recalls 10,000+ Pounds of Candy Over Allergy Risk
- Listen to the Latest ‘KFF Health News Minute’
- The new playbook for clinician well-being
- Estados cambian leyes para evitar que hijos de inmigrantes detenidos entren al sistema de cuidado temporal
- Keebler Health secures $16M in series A funding for AI-powered risk adjustment platform
- Sam’s Club Recalls Children’s Pajamas Due to Fire Hazard
- Small Talk? It May Be Better Than You Think
- Cómo hacer que un plan de salud con deducible alto funcione para tí
- Anthem, Mount Sinai reach contract agreement, restore in-network coverage
- J&J, chasing $100B year, sports immunology ‘dual powerhouse’ of Tremfya and new launch Icotyde
- Stanford Health Care, Alameda Health System partner to support St. Rose Hospital
- Para muchos pacientes que salen de terapia intensiva, la lucha apenas comienza
- Long-Term Opioid Prescriptions Fall By About A Quarter
- Gut Bacteria Might Drive Rare Food Allergy in Children, Study Finds
- Stents Can Ease Long-Term Symptoms Of Deep Vein Thrombosis, Trial Shows
- Young Cancer Survivors Face Doubled Risk Of Subsequent New Cancer
- Does Your Child Have Nightmares? Here's One Solution
- Marriage's Hidden Benefit? A Lower Risk Of Cancer
- Novo taps OpenAI to deploy AI across R&D, manufacturing and corporate functions
- Los estados se enfrentan a otro reto con las nuevas reglas laborales de Medicaid: la falta de personal
- States Change Custody Laws To Keep Children of Detained Immigrants Out of Foster Care
- WebMD Ignite rolls out program to help providers get Rural Health Transformation efforts off the ground
- Pfizer rebuked by FDA for misleading Adcetris ads on Facebook
- NewYork-Presbyterian to enact behavioral health reforms, pay $500K in wake of investigation
- FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results
- FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results
- Freedom of Associations
- Interfacing with our Inner Demons: Comments on the Division of Trading and Markets' Statement on Certain User Interfaces
- New Mental Health Parity Index highlights where disparities persist
- CMS taps 150 digital health companies, providers for ACCESS Model
- Wavelet Medical, Aegis Ventures partner on first AI non-invasive fetal EEG monitoring platform
- Staff Statement Regarding Broker-Dealer Registration of Certain User Interfaces Utilized to Prepare Transactions in Crypto Asset Securities
- New Rules May Allow Broader Picks for CDC Vaccine Panel
- Second Meningitis Vaccine Doses Offered After U.K. Outbreak
- Crackdown on Vapes Falling Short, Report Finds
- Jasmine Rice Recalled Nationwide Over Possible Contamination
- ‘The next opioid epidemic’: Gambling legalization outpaces public health response to addiction
- Thinking About A GLP-1 Drug? Your Genetics Might Determine How Well You'll Fare
- Fighting High Blood Pressure? Having A Team On Your Side Can Help
- Radon Gas Increases Risk Of Ovarian Cancer, Study Says
- Your Doctor Might Be Using The Wrong Test To Track Your Cholesterol, Study Says
- Losing Teeth May Lead to Weight Gain, Researchers Report
- Heart Risk Worse With Sleep Apnea That Varies Night-By-Night
- Lilly’s Jaypirca shows fixed-duration power in ‘ambitious’ phase 3 CLL trial win
- ViiV launches ‘Still Here’ campaign aimed at reminding young people about HIV
- Regeneron rides into radiopharma via $2.1B biobucks pact with Australia’s Telix
- Statement Regarding Staff No-Action Letter to Bank of England
- The Healthcare Burnout Backlash (pt 3): How Workflow Redesign Is Helping Healthcare Organizations Offset Staffing Shortages
- The Healthcare Burnout Backlash (pt 3): How Workflow Redesign Is Helping Healthcare Organizations Offset Staffing Shortages
- BD Announced Application of CE Mark for the Liverty TIPS Stent Graft
- BD Announced Application of CE Mark for the Liverty TIPS Stent Graft
An Ohio telehealth company called Hims and Hers Health introduced a compounded, $ 49 per month GLP-1 agonist pill to the market yesterday and chaos has reigned in the pharmaceutical space ever since:
Exclusive: Hims offers cheapest GLP-1 weight-loss pill in US in a shock to Novo, Lilly
By Amina Niasse - February 5, 2026Summary
- Hims and Hers Health will offer the drugs at a price $100 cheaper than the brand-name offerings
- Novo Nordisk shares fall to lowest level since 2021
- Novo says it is considering legal action
NEW YORK, Feb 5 (Reuters) - Online telehealth company Hims and Hers Health (HIMS.N) on Thursday began offering a much cheaper $49 compounded version of Novo Nordisk's (NOVOb.CO) new Wegovy weight-loss pill in a move that expands sales to many Americans but could undercut Novo's and Eli Lilly's (LLY.N) plans for the consumer market.
The news touched off a swift reaction on Wall Street as investors sold off Novo and Lilly shares, and the Danish drugmaker promised a legal challenge to the move by Hims. Novo shares fell 8.6%, while Lilly was off (LLY.N) 6%.
Hims' pricing, $49 for the first month and $99 afterwards for those who purchase a five-month plan, makes their GLP-1 drug as affordable as monthly internet or streaming services in the U.S. It can offer access to treatment for many more of the estimated 200 million Americans who are overweight or obese.
It is $100 less than Novo, which launched its pill in January at $149 for first-time users and $199 after that. Lilly is expected to launch its pill in April and has promised the Trump Administration affordable pricing including on its new TrumpRx site.
Hims' move came after Novo warned on Wednesday that pricing pressure was unprecedented for its weight-loss medicines and dropped its full-year forecast. Novo shares on Thursday hit their lowest level since July 2021.
NOVO SAYS ITS PILL IS UNIQUE
Novo CEO Mike Doustdar in a meeting with investors on Thursday said people spending $49 on a Hims' pill would be wasting their money and that Novo's pill uses unique technology that aids in the absorption of the medicine.
Novo spokeswoman Ambre James-Brown described Hims' mass compounding as illegal. "Novo Nordisk will take legal and regulatory action to protect patients, our intellectual property and the integrity of the U.S. gold-standard drug approval framework," she said.
A Hims spokesperson said it has not compromised on safety or efficacy and that the company uses a technology based on liposomes that is intended to support absorption.
Analysts questioned if customers would get similar results on the cheaper pill but said it could drive a price war if compounders can provide an oral drug in large quantities.
Hims has been tussling with Novo since it was allowed in 2023 by the U.S. Food and Drug Administration to sell versions of Novo's GLP-1 injectible drugs while the branded medicines were in short supply. Since then, it has made "personalized" copies of the branded drugs at different doses or regimens than those available from Novo and other drug companies.
These drugs are not FDA approved and are subject to limited agency oversight. They also do not go through clinical trials to prove efficacy. Novo's Wegovy pill showed weight loss of more than 16% in trials.
"The status quo for months now has been a compounder can create a copycat version of a branded drug, so long as they make some kind of minor tweak that they believe or they argue benefits specific patient groups," said TD Cowen analyst Michael Nedelcovych.
HIMS MAKES CASE FOR MORE CHOICE
Hims said the treatment can be tailored for patients aiming to mitigate side effects or who prefer a pill over the injectable option. Semaglutide is the main ingredient in the new Wegovy pill as well as injectable Wegovy and Ozempic.
"We're excited to find ways to continue bringing branded treatments to the platform across specialties. More choice on the platform is the best thing for customers everywhere," said Hims CEO Andrew Dudum in a statement.
Novo and Hims had a partnership in 2025 allowing the telehealth company to offer injectable Wegovy, but the two companies walked away with Novo saying Hims had wrongfully marketed versions of its medicine. Dudum accused Novo of attempting to control how clinicians at Hims make decisions.
By tailoring its offering for patients with side effects or an aversion to needles, Gaston Kroub, a patent lawyer in New York, said Hims is positioning the oral product as another personalized option, widening the scope of personalization under the FDA’s framework.
"HIMS has shown a willingness to go as close to the line as possible,” he said. “It’s a strategy of saying, ‘All right, if we pop our head over the barbed wire fence, is anybody going to take a shot?’”
Novo launched the drug in the beginning of January and has seen strong demand in the U.S., where it is available on its cash-pay direct-to-consumer website.
Novo Chief Financial Officer Karsten Munk Knudsen told Reuters on Wednesday that the drugmaker is frustrated by continued mass marketing of compounded drugs, and said it was up to the U.S. regulator and politicians to address this.
The FDA in September issued a warning to Hims regarding its marketing of compounded semaglutide, stating claims like "same active ingredient as Ozempic and Wegovy" are misleading, as compounded drugs are not FDA-approved.
LILLY PILL IS NEXT UP
In addition to U.S. pricing pressure, Novo is girding for competition from Eli Lilly on the oral weight-loss front as the Indianapolis-based drugmaker expects to launch its own pill in the second quarter.
Some analysts said Lilly's pill, an experimental GLP-1, could be a next target for compounded copies. Compounding, in which pharmacies mix ingredients for specialized medicines or to copy a drug but at different dosages, has flourished as Americans chase cheaper prices for drugs.
Hims declined to comment on the drug. Lilly did not have an immediate comment.
In 2025, Hims doubled the size of its facility in New Albany, Ohio. The company said on Thursday the expansion allows Hims to provide treatments at a lower price.
In response to the Hims and Hers Health GLP-1 receptor agonist pill offering, FDA Commissioner Marty Makary says that the Food and Drug Administration will "take swift action" against companies mass-marketing illegal copycat drugs. Uppermost on his mind is undoubtedly the New England Compounding Center (NECC) in Framingham, Massachusetts whose contaminated injectable epidural steroids caused a fungal meningitis outbreak in 2012 which killed more than 64 people, including 11 here in Michigan:
Novo Nordisk shares rebound as FDA targets illegal drug copies
By Jacob Gronholt-Pedersen - February 6, 2026COPENHAGEN, Feb 6 (Reuters) - Shares in Danish drugmaker Novo Nordisk (NOVOb.CO) gained 5.4% on Friday, recovering some of the previous two sessions' steep losses, after the U.S. Food and Drug Administration (FDA) pledged to address mass-marketing of unapproved drugs.
The stock plunged nearly 8% on Thursday after telehealth company Hims and Hers Health (HIMS.N) launched a significantly cheaper $49 compounded version of Novo Nordisk's FDA-approved Wegovy weight-loss pill.
Novo's shares, which are near their lowest since Wegovy was introduced in June 2021, were 5.4% higher at 1341 GMT.
Late on Thursday, FDA Commissioner Marty Makary said on X that the agency would "take swift action" against companies mass-marketing illegal copycat drugs. "The FDA cannot verify the quality, safety or effectiveness of non-approved drugs," he said without naming any companies.
Despite the FDA statement, Bernstein analyst Christian Moore said he wasn't holding his breath for U.S. authorities to take decisive action.
"We do think people will still buy it, and don’t think the government will do anything to stop it, based on precedent," he said.
The FDA and individual states share regulatory authority over compounding pharmacies. In September, it launched a new tracker to show when ingredients were coming from FDA-inspected facilities. It also sent letters that month to companies it said were practicing deceptive direct-to-consumer advertising, including Hims, Novo, and rival Eli Lilly (LLY.N).
Novo, which on Wednesday flagged unprecedented price pressure that saw its stock plunge 17%, said on Thursday it would take "legal and regulatory action" in response to Hims' announcement but declined to elaborate further on Friday.
Eli Lilly, which is awaiting a U.S. regulatory decision on its weight-loss pill orforglipron, was also critical of the launch announcement.
"Patients deserve better than untested knockoffs that are sold without clinical evidence that they even work," a Lilly spokesperson said in an email to Reuters on Thursday before Makary's public post.A Hims spokesperson said on Thursday the company had not compromised on safety or efficacy and used a technology based on liposomes intended to support absorption, in response to similar criticisms from Novo.
Lilly's shares, which had ended the prior session down about 8%, rose 3.8% in premarket trading.
($1 = 6.3327 Danish crowns)
Hims & Hers Health folds:
https://x.com/HimsHersComms/status/2020207947645911214
PostHims & Hers Comms
@HimsHersCommsSince launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment. We remain committed to the millions of Americans who depend on us for access to safe, affordable, and personalized care.
This may change in March, when Novo Nordisk's compound patent expires.
Novo Nordisk filed suit against Hims & Hers:
Novo Nordisk sues Hims & Hers over patent infringement
By Stine Jacobsen - February 9, 2026COPENHAGEN, Feb 9 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Monday it has filed a lawsuit against U.S. telehealth company Hims & Hers (HIMS.N), opens new tab for infringing on the Danish group's patents.
"Novo Nordisk is asking the court to permanently ban Hims from selling unapproved, compounded drugs that infringe our patents, and is seeking to recover damages," the Danish drugmaker said in a statement.
The move comes after Hims on Saturday cancelled the launch of a $49 copy of a weight-loss pill from Novo Nordisk and the U.S. Food and Drug Administration.
The Hims and Hers' reply:
https://x.com/HimsHersComms/status/2020854864666923411
PostHims & Hers Comms
@HimsHersCommsNovo Nordisk’s lawsuit is a blatant attack by a Danish company on millions of Americans who rely on compounded medications for access to personalized care. Once again, Big Pharma is weaponizing the US judicial system to limit consumer choice. This lawsuit attacks more than just one medication or company – it directly assaults a well-established, vital component of US pharmacy practice that has improved patient care for everything from obesity to infertility to cancer. Hims & Hers has a long history of providing safe access to personalized healthcare to millions of Americans, and we will continue to fight to provide choice, affordability, and access.
8:38 AM · February 9, 2026
Hims & Hers Health falls on its financial sword:
Hims & Hers forecasts first-quarter sales below estimates, shares fall
By Sneha S K in Bengaluru; Editing by Alan Barona - February 23, 2026Summary
- Shares fall 7% after hours
- Personalized weight-loss products generate $65 million headwind in Q1
- Overseas expansion to boost growth in non-weight-loss business
Feb 23 (Reuters) - Online telehealth company Hims & Hers Health (HIMS.N), which sells weight-loss drugs, hormone replacement therapies and health services, on Monday forecast first-quarter revenue below estimates, pushing its shares down 7% in after-hours trading.
The company said that the first quarter would be facing a $65 million burden from changes in the shipping of weight-loss products, which must be personalized for each prescription based on U.S. law.
Hims and Hers has grown rapidly as customers flocked to its cheap weight-loss drugs, which include compounded injectable versions of Novo Nordisk's highly popular Wegovy. Since those drugs are no longer in shortage, Hims is only allowed to make the medicines for customers if the dosage or ingredients are personalized.
Hims' efforts to launch compounded copies of Novo's new Wegovy pill at an introductory price of $49 per month were cut down earlier this month by the U.S. Food and Drug Administration, which said it would take action against it and other companies and referred Hims to the Department of Justice. Hims said in a regulatory filing that it is unclear what actions the regulators and DOJ may pursue. Novo also filed a patent suit against the company.
The stock is down 52% so far this year. Still, the company gave a 2026 outlook with the midpoint above analysts' estimates and vowed to stay on course.
"We plan to continue to operate like we always have," said CEO Andrew Dudum, who added the company is systematically broadening and diversifying its offerings. "It's important to remember that the majority of our revenue and profitability is driven by offerings outside of weight loss."
Hims and Hers forecast revenue of $600 million to $625 million for the first quarter, missing estimates of $653.11 million, according to data compiled by LSEG.
Hims also expects 2026 revenue to be in the range of $2.7 billion to $2.9 billion, compared to estimates of $2.74 billion.
REGULATORY RISK FUELS UNCERTAINTY
International expansion may help it grow but does not address the continuity of the company's weight-loss business, which remains uncertain due to regulatory risks, said Michael Cherny, an analyst at Leerink Partners.
"It would widen the long-term opportunity, but the more important component for the stock is how Hims progresses with its weight-loss business," Cherny said.
The company said its outlook gives "flexibility to lean into future investments" and said it will keep Hims on track for its 2030 target of more than $6.5 billion in revenue.
Hims last week said it will acquire Australian digital health company Eucalyptus in a deal valued at up to $1.15 billion. Analysts said the deal could accelerate growth for the company's non-weight-loss offerings.
Subscribers rose to 2.5 million, up 13% from the prior year.
It reported quarterly revenue of $617.8 million, an increase of 28% year-over-year, but below the analysts' average estimate of $619.22 million.
The company's product costs increased over 30%, a regulatory filing showed.
Hims' investment in its Super Bowl ad will also raise first-quarter operating costs, CFO Yemi Okupe said.
Novo Nordisk A/S and Hims & Hers Health Inc. have kissed and made up. Novo and Hims will announce a new partnership to sell GLP-1 receptor agonist drugs Monday:
Novo and Hims to sell obesity drugs together as feud ends, Bloomberg News reports
By Carlos Méndez in Mexico City and Mihika Sharma in Bengaluru - March 6, 2026March 6 (Reuters) - Wegovy maker Novo Nordisk (NOVOb.CO), opens new tab plans to sell its weight-loss drugs on Hims & Hers Health (HIMS.N), opens new tab platform, bringing an end to a dispute between the two companies that escalated into a legal battle last month, Bloomberg News reported on Friday.
Hims shares surged 39% in after-hours trading after the report.
The report comes nearly a month after Novo sued Hims over patent infringement following the U.S. telehealth firm's launch, and then cancellation, of a $49 copy of Novo's obesity pill.
The U.S. Food and Drug Administration had also threatened action against Hims.
Novo and Hims plan to announce a new partnership as soon as Monday, the report said, citing a person familiar with the matter.
Last year, Novo ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims over the company's marketing tactics and continued sales of Wegovy copies.
A Novo spokesperson said in an e-mailed statement the company is "always in conversation with companies that can help improve patient access to FDA-approved medicines".
Hims did not immediately respond to a request for comment.
The power of the greenback on full display! 😍
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.
Sponsors
J & DE Family Charitable Fund
Friends
of MHF
Kelly Grotendiek
Philip Harbach
Dale Johnson
Drs. Jeffrey and Joni Jones
Vickie Kahle
Tammy Kipen
Marlin & Kathy Klumpp
Melanie Kurdys
Ruth Nobel
Patrick Peterson
Stephanie Poortenga
Jeanne Smit
Ben and Hope Staal
John Tuinstra
Jacki VanHuis
Sandy Walker
Sign Up for MHF Insights to keep up on the latest in Michigan Health Policy
